Myelin oligodendrocyte glycoprotein (MOG) has recently been identified as the target in a spectrum of autoimmune conditions of the central nervous system, now referred to as MOG antibody-associated disease (MOGAD). Using advanced molecular technologies, Dr. Zamvil is working to identify and characterize MOG-specific T cells and antibodies in MOGAD, to better define the disease process and possibly lead to development of novel MOG-targeted therapies.
